

# Samit R Joshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033335/publications.pdf>

Version: 2024-02-01

8  
papers

110  
citations

1478505

6  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

32  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as) Tj ETQq1 1 0.784314 rgBT /Overl... primary analysis from a randomized Phase IIb trial. PLoS ONE, 2018, 13, e0205368.	2.5	29
2	Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacology Research and Perspectives, 2020, 8, e00671.	2.4	21
3	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. PLoS ONE, 2019, 14, e0224076.	2.5	15
4	Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults. British Journal of Clinical Pharmacology, 2021, 87, 3501-3507.	2.4	12
5	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. Clinical Infectious Diseases, 2022, 75, 786-794.	5.8	12
6	A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	11
7	Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women. British Journal of Clinical Pharmacology, 2022, 88, 1704-1712.	2.4	5
8	Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants. Clinical Pharmacology in Drug Development, 2022, 11, 632-639.	1.6	5